| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | CD300LG; CLM9; TREM4; CMRF35-like molecule 9; CLM-9; CD300 antigen-like family member G; Triggering receptor expressed on myeloid cells 4; TREM-4; CD300g |
| Clonality | |
| Concentration | |
| Formulation | |
| Gene ID | |
| Host | |
| Immunogen | The antiserum was produced against synthesized peptide derived from the Internal region of human CD300LG. AA range:41-90 |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Storage | |
| Target |
Product Overview
Primary AntibodyThis antibody targets CD300LG and detects endogenous levels of CD300LG protein.
Validated Applications
| Application | Dilution Guidance |
|---|---|
| Western Blot (WB) | Refer to datasheet for recommended working dilution |
| Immunohistochemistry (IHC) | Refer to datasheet for recommended working dilution |
| ELISA | Refer to datasheet for recommended working dilution |
Antibody Specifications
| Target | CD300LG |
|---|---|
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Reactivity | Human |
| Purification | Affinity Purification |
| Molecular Weight | ~36.1 kDa |
| Concentration | 1 mg/ml |
| Immunogen | The antiserum was produced against synthesized peptide derived from the Internal region of human CD300LG. AA range:41-90 |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Storage | -20°C for 1 year |
| Gene ID | Human: 146894; Mouse: 52685 |
| UniProt | Q6UXG3 (Human: Q6UXG3; Mouse: Q1ERP8) |
Scientific Background
Members of the CD300 (see MIM 606786)-like (CD300L) family, such as CD300LG, are widely expressed on hematopoietic cells. All CD300L proteins are type I cell surface glycoproteins that contain a single immunoglobulin (Ig) V-like domain.
Alternative Names
CD300LG; CLM9; TREM4; CMRF35-like molecule 9; CLM-9; CD300 antigen-like family member G; Triggering receptor expressed on myeloid cells 4; TREM-4; CD300g
Safety & Handling
| Target | CD300LG |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Reactivity | Human |
| Purification | Affinity Purification |
| Molecular Weight | ~36.1 kDa |
| Concentration | 1 mg/ml |
| Immunogen | The antiserum was produced against synthesized peptide derived from the Internal region of human CD300LG. AA range:41-90 |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Storage | -20°C for 1 year |
| Gene ID | Human: 146894; Mouse: 52685 |
| UniProt | Q6UXG3 (Human: Q6UXG3; Mouse: Q1ERP8) |
Optimized working dilutions depend on sample type and detection system. Titration is recommended.
| Application | Dilution Note |
|---|---|
| Western Blot (WB) | Refer to datasheet for recommended working dilution |
| Immunohistochemistry (IHC) | Refer to datasheet for recommended working dilution |
| ELISA | Refer to datasheet for recommended working dilution |
Members of the CD300 (see MIM 606786)-like (CD300L) family, such as CD300LG, are widely expressed on hematopoietic cells. All CD300L proteins are type I cell surface glycoproteins that contain a single immunoglobulin (Ig) V-like domain.
Alternative Names
CD300LG; CLM9; TREM4; CMRF35-like molecule 9; CLM-9; CD300 antigen-like family member G; Triggering receptor expressed on myeloid cells 4; TREM-4; CD300g
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
